News

Video

MPN Survivor Discusses Her Biggest Regret After Being Diagnosed

Author(s):

After being diagnosed with essential thrombocythemia, Marilyn Kay Edwards was not told much about her disease.

When Marilyn Kay Edwards was diagnosed with essential thrombocythemia in 1986, she was told to just continue living her life. Doctors told Edwards, who was pregnant at the time, to continue taking aspirin and watch the pregnancy, and get her blood checked every year to a year and a half. In fact, at that time, myeloproliferative neoplasms (MPNs) like essential thrombocythemia were not even classified as cancers.

Edwards said that she was not told that her essential thrombocythemia could turn into a more serious type of MPN called myelofibrosis, which she was later diagnosed with in 2017. In a recent interview with CURE®, she expressed that she wishes she was more involved with her care and learned more about her disease. She said if she had been, then she could have potentially started treatments for her disease.

Now, Edwards is an MPN Peer with the Voices of MPN CHAMPN program. She uses her experience to help guide others who recently received a diagnosis of an MPN.

Transcription

I've learned that I should have been more involved in my diagnosis because I did not understand what I had at all. And I just kind of kept my head in the sand. And then in 2017, I got very sick and whenever they told me what was wrong, I had never heard of it before. And then when you Google it, it's not good.

So, I've learned to tell people “Don't Google myelofibrosis.” And I should have been more involved with what was happening. That's probably my biggest regret because I actually missed out on treatments that I could have had earlier that I didn't know about.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content